Related Experiment Video
Updated: Jul 3, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Managing the Diagnostic and Therapeutic Challenges of Irritable Bowel Syndrome
Jessica C Petrov1, Brian E Lacy1, David J Cangemi1
1Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida.
Abstract:
The management of patients with irritable bowel syndrome (IBS) remains a common clinical challenge for health care providers. IBS is a prevalent disorder that encompasses a constellation of symptoms that may be caused by a variety of underlying conditions; as a result, there is no one-size-fits-all approach, and clinicians must tailor their approach to the individual. This article outlines the challenges associated with the management of IBS and offers practical solutions to help providers care for patients with IBS.
Related Concept Videos
Irritable Bowel Syndrome III: Medical and Nursing Management
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Irritable Bowel Syndrome
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...